Stay updated on Adjunctive KarXT in Schizophrenia Clinical Trial
Sign up to get notified when there's something new on the Adjunctive KarXT in Schizophrenia Clinical Trial page.

Latest updates to the Adjunctive KarXT in Schizophrenia Clinical Trial page
- Check5 days agoChange DetectedUpdated the page’s displayed ClinicalTrials.gov revision from **v3.5.2** to **v3.5.3**.SummaryDifference0.1%

- Check12 days agoChange DetectedRevision: v3.5.2 was added and Revision: v3.5.0 was removed.SummaryDifference0.1%

- Check20 days agoChange DetectedAdded access to core study data sections such as Adverse Events, Outcome Measures (Results), Baseline Characteristics, and Participant Flow, along with More Information and Quality Control status.SummaryDifference0.7%

- Check28 days agoChange DetectedSponsor name updated from Karuna Therapeutics to Karuna Therapeutics, Inc., a Bristol Myers Squibb company. This aligns the sponsor with current corporate ownership and ensures accurate attribution on the study record.SummaryDifference0.1%

- Check42 days agoChange DetectedAdded: Results Submitted and Revision: v3.5.0; Removed: No Results Posted and Revision: v3.4.3. These changes indicate that results have been submitted and the page revision has been updated.SummaryDifference0.1%

- Check50 days agoChange DetectedThe page's revision label changed from v3.4.2 to v3.4.3. This is a minor metadata update reflecting a new release version.SummaryDifference0.1%

Stay in the know with updates to Adjunctive KarXT in Schizophrenia Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjunctive KarXT in Schizophrenia Clinical Trial page.